Technical Analysis for ALVR - AlloVir, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 200 DMA | Bearish | 0.00% | |
Earnings Movers | Other | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Bearish Engulfing | Bearish | -5.63% | |
Upper Bollinger Band Walk | Strength | -5.63% | |
Wide Bands | Range Expansion | -5.63% | |
Overbought Stochastic | Strength | -5.63% | |
Down 3 Days in a Row | Weakness | -5.63% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Down 5% | about 9 hours ago |
Fell Below 10 DMA | about 9 hours ago |
10 DMA Support | about 10 hours ago |
200 DMA Support | about 10 hours ago |
Fell Below 200 DMA | about 10 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/08/2023
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Immune System Stem Cell Gene Therapy Cell Biology Cell Therapy Manufacturing Process Proprietary Technology Viruses Viral Disease Virus Immunity Zoonoses Shimon Slavin Covid 19
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Immune System Stem Cell Gene Therapy Cell Biology Cell Therapy Manufacturing Process Proprietary Technology Viruses Viral Disease Virus Immunity Zoonoses Shimon Slavin Covid 19
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 10.29 |
52 Week Low | 3.17 |
Average Volume | 230,875 |
200-Day Moving Average | 6.19 |
50-Day Moving Average | 6.00 |
20-Day Moving Average | 5.78 |
10-Day Moving Average | 6.12 |
Average True Range | 0.42 |
RSI | 52.15 |
ADX | 20.55 |
+DI | 28.14 |
-DI | 17.43 |
Chandelier Exit (Long, 3 ATRs) | 5.70 |
Chandelier Exit (Short, 3 ATRs) | 6.21 |
Upper Bollinger Bands | 6.69 |
Lower Bollinger Band | 4.88 |
Percent B (%b) | 0.64 |
BandWidth | 31.15 |
MACD Line | 0.14 |
MACD Signal Line | 0.03 |
MACD Histogram | 0.1097 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 6.61 | ||||
Resistance 3 (R3) | 6.67 | 6.55 | 6.52 | ||
Resistance 2 (R2) | 6.55 | 6.40 | 6.52 | 6.48 | |
Resistance 1 (R1) | 6.29 | 6.31 | 6.23 | 6.23 | 6.45 |
Pivot Point | 6.17 | 6.17 | 6.14 | 6.14 | 6.17 |
Support 1 (S1) | 5.91 | 6.02 | 5.85 | 5.85 | 5.63 |
Support 2 (S2) | 5.79 | 5.93 | 5.76 | 5.60 | |
Support 3 (S3) | 5.53 | 5.79 | 5.57 | ||
Support 4 (S4) | 5.47 |